Selected research
Industry Research
Melanoma Drugs Industry Research Report 2026
Market perspective
The global Melanoma Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Melanoma Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Melanoma Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Melanoma Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Melanoma Drugs include Grand Pharmaceutical (China) Co., Ltd, Innovent Biologics, Sanofi, Novartis, Merck Group, Roche, Shanghai Junshi Biosciences Co.,Ltd, Pfizer and Jiangsu Hengrui Medicine Co.,Ltd., among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Melanoma Drugs market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Melanoma Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Melanoma Drugs Market by Company
Grand Pharmaceutical (China) Co., Ltd
Innovent Biologics
Sanofi
Novartis
Merck Group
Roche
Shanghai Junshi Biosciences Co.,Ltd
Pfizer
Jiangsu Hengrui Medicine Co.,Ltd.
Bristol-Myers Squibb
BeiGene, Ltd.
Amgen
Teva Pharma
Takeda Pharma
Janssen Biotech
Genentech
Melanoma Drugs Segment by Type
Immunotherapy
Chemotherapy
Targeted Therapy
Melanoma Drugs Segment by Application
Hospitals
Clinics
Others
Melanoma Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Melanoma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Melanoma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Melanoma Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Melanoma Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Immunotherapy
- Chemotherapy
- Targeted Therapy
Applications
- Hospitals
- Clinics
- Others
Companies covered
- Grand Pharmaceutical (China) Co., Ltd
- Innovent Biologics
- Sanofi
- Novartis
- Merck Group
- Roche
- Shanghai Junshi Biosciences Co.,Ltd
- Pfizer
- Jiangsu Hengrui Medicine Co.,Ltd.
- Bristol-Myers Squibb
- BeiGene, Ltd.
- Amgen
- Teva Pharma
- Takeda Pharma
- Janssen Biotech
- Genentech
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Melanoma Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Immunotherapy
- 2.2.3 Chemotherapy
- 2.2.4 Targeted Therapy
- 2.3 Melanoma Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospitals
- 2.3.3 Clinics
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Melanoma Drugs Breakdown Data by Type
- 3.1 Global Melanoma Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Melanoma Drugs Forecasted Market Size by Type (2027-2032)
4 Melanoma Drugs Breakdown Data by Application
- 4.1 Global Melanoma Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Melanoma Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Melanoma Drugs Market Perspective (2021-2032)
- 5.2 Global Melanoma Drugs Growth Trends by Region
- 5.2.1 Global Melanoma Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Melanoma Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Melanoma Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Melanoma Drugs Market Dynamics
- 5.3.1 Melanoma Drugs Industry Trends
- 5.3.2 Melanoma Drugs Market Drivers
- 5.3.3 Melanoma Drugs Market Challenges
- 5.3.4 Melanoma Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Melanoma Drugs Players by Revenue
- 6.1.1 Global Top Melanoma Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Melanoma Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Melanoma Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Melanoma Drugs Head Office and Area Served
- 6.4 Global Melanoma Drugs Players, Product Type & Application
- 6.5 Global Melanoma Drugs Manufacturers Established Date
- 6.6 Global Melanoma Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Melanoma Drugs Market Size (2021-2032)
- 7.2 North America Melanoma Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Melanoma Drugs Market Size by Country (2021-2026)
- 7.4 North America Melanoma Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Melanoma Drugs Market Size (2021-2032)
- 8.2 Europe Melanoma Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Melanoma Drugs Market Size by Country (2021-2026)
- 8.4 Europe Melanoma Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Melanoma Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Melanoma Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Melanoma Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Melanoma Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Melanoma Drugs Market Size (2021-2032)
- 10.2 South America Melanoma Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Melanoma Drugs Market Size by Country (2021-2026)
- 10.4 South America Melanoma Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Melanoma Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Melanoma Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Melanoma Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Melanoma Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Grand Pharmaceutical (China) Co., Ltd
- 12.1.1 Grand Pharmaceutical (China) Co., Ltd Company Information
- 12.1.2 Grand Pharmaceutical (China) Co., Ltd Business Overview
- 12.1.3 Grand Pharmaceutical (China) Co., Ltd Revenue in Melanoma Drugs Business (2021-2026)
- 12.1.4 Grand Pharmaceutical (China) Co., Ltd Melanoma Drugs Product Portfolio
- 12.1.5 Grand Pharmaceutical (China) Co., Ltd Recent Developments
- 12.2 Innovent Biologics
- 12.2.1 Innovent Biologics Company Information
- 12.2.2 Innovent Biologics Business Overview
- 12.2.3 Innovent Biologics Revenue in Melanoma Drugs Business (2021-2026)
- 12.2.4 Innovent Biologics Melanoma Drugs Product Portfolio
- 12.2.5 Innovent Biologics Recent Developments
- 12.3 Sanofi
- 12.3.1 Sanofi Company Information
- 12.3.2 Sanofi Business Overview
- 12.3.3 Sanofi Revenue in Melanoma Drugs Business (2021-2026)
- 12.3.4 Sanofi Melanoma Drugs Product Portfolio
- 12.3.5 Sanofi Recent Developments
- 12.4 Novartis
- 12.4.1 Novartis Company Information
- 12.4.2 Novartis Business Overview
- 12.4.3 Novartis Revenue in Melanoma Drugs Business (2021-2026)
- 12.4.4 Novartis Melanoma Drugs Product Portfolio
- 12.4.5 Novartis Recent Developments
- 12.5 Merck Group
- 12.5.1 Merck Group Company Information
- 12.5.2 Merck Group Business Overview
- 12.5.3 Merck Group Revenue in Melanoma Drugs Business (2021-2026)
- 12.5.4 Merck Group Melanoma Drugs Product Portfolio
- 12.5.5 Merck Group Recent Developments
- 12.6 Roche
- 12.6.1 Roche Company Information
- 12.6.2 Roche Business Overview
- 12.6.3 Roche Revenue in Melanoma Drugs Business (2021-2026)
- 12.6.4 Roche Melanoma Drugs Product Portfolio
- 12.6.5 Roche Recent Developments
- 12.7 Shanghai Junshi Biosciences Co.,Ltd
- 12.7.1 Shanghai Junshi Biosciences Co.,Ltd Company Information
- 12.7.2 Shanghai Junshi Biosciences Co.,Ltd Business Overview
- 12.7.3 Shanghai Junshi Biosciences Co.,Ltd Revenue in Melanoma Drugs Business (2021-2026)
- 12.7.4 Shanghai Junshi Biosciences Co.,Ltd Melanoma Drugs Product Portfolio
- 12.7.5 Shanghai Junshi Biosciences Co.,Ltd Recent Developments
- 12.8 Pfizer
- 12.8.1 Pfizer Company Information
- 12.8.2 Pfizer Business Overview
- 12.8.3 Pfizer Revenue in Melanoma Drugs Business (2021-2026)
- 12.8.4 Pfizer Melanoma Drugs Product Portfolio
- 12.8.5 Pfizer Recent Developments
- 12.9 Jiangsu Hengrui Medicine Co.,Ltd.
- 12.9.1 Jiangsu Hengrui Medicine Co.,Ltd. Company Information
- 12.9.2 Jiangsu Hengrui Medicine Co.,Ltd. Business Overview
- 12.9.3 Jiangsu Hengrui Medicine Co.,Ltd. Revenue in Melanoma Drugs Business (2021-2026)
- 12.9.4 Jiangsu Hengrui Medicine Co.,Ltd. Melanoma Drugs Product Portfolio
- 12.9.5 Jiangsu Hengrui Medicine Co.,Ltd. Recent Developments
- 12.10 Bristol-Myers Squibb
- 12.10.1 Bristol-Myers Squibb Company Information
- 12.10.2 Bristol-Myers Squibb Business Overview
- 12.10.3 Bristol-Myers Squibb Revenue in Melanoma Drugs Business (2021-2026)
- 12.10.4 Bristol-Myers Squibb Melanoma Drugs Product Portfolio
- 12.10.5 Bristol-Myers Squibb Recent Developments
- 12.11 BeiGene, Ltd.
- 12.11.1 BeiGene, Ltd. Company Information
- 12.11.2 BeiGene, Ltd. Business Overview
- 12.11.3 BeiGene, Ltd. Revenue in Melanoma Drugs Business (2021-2026)
- 12.11.4 BeiGene, Ltd. Melanoma Drugs Product Portfolio
- 12.11.5 BeiGene, Ltd. Recent Developments
- 12.12 Amgen
- 12.12.1 Amgen Company Information
- 12.12.2 Amgen Business Overview
- 12.12.3 Amgen Revenue in Melanoma Drugs Business (2021-2026)
- 12.12.4 Amgen Melanoma Drugs Product Portfolio
- 12.12.5 Amgen Recent Developments
- 12.13 Teva Pharma
- 12.13.1 Teva Pharma Company Information
- 12.13.2 Teva Pharma Business Overview
- 12.13.3 Teva Pharma Revenue in Melanoma Drugs Business (2021-2026)
- 12.13.4 Teva Pharma Melanoma Drugs Product Portfolio
- 12.13.5 Teva Pharma Recent Developments
- 12.14 Takeda Pharma
- 12.14.1 Takeda Pharma Company Information
- 12.14.2 Takeda Pharma Business Overview
- 12.14.3 Takeda Pharma Revenue in Melanoma Drugs Business (2021-2026)
- 12.14.4 Takeda Pharma Melanoma Drugs Product Portfolio
- 12.14.5 Takeda Pharma Recent Developments
- 12.15 Janssen Biotech
- 12.15.1 Janssen Biotech Company Information
- 12.15.2 Janssen Biotech Business Overview
- 12.15.3 Janssen Biotech Revenue in Melanoma Drugs Business (2021-2026)
- 12.15.4 Janssen Biotech Melanoma Drugs Product Portfolio
- 12.15.5 Janssen Biotech Recent Developments
- 12.16 Genentech
- 12.16.1 Genentech Company Information
- 12.16.2 Genentech Business Overview
- 12.16.3 Genentech Revenue in Melanoma Drugs Business (2021-2026)
- 12.16.4 Genentech Melanoma Drugs Product Portfolio
- 12.16.5 Genentech Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst